Form 4: Aura Biosciences Director David Johnson Boosts Equity Stake with RSU and Option Awards

Aura Biosciences Director David Michael Johnson has increased his beneficial ownership in the company through the acquisition of 13,000 restricted stock units and 17,000 stock options, as reported in a recent SEC Form 4 filing.

Summary

• David Michael Johnson, a Director of Aura Biosciences, Inc. (AURA), reported changes in his beneficial ownership via an SEC Form 4 filing.
• On June 17, 2025, Mr. Johnson acquired 13,000 shares of Common Stock through a Restricted Stock Unit (RSU) award at a price of $0.
• These RSUs are set to vest in full upon the earlier of June 17, 2026, or the next annual meeting of the Issuer's stockholders, contingent on his continued service.
• Additionally, he acquired 17,000 stock options with an exercise price of $6.18 per share, which will expire on June 17, 2035.
• These stock options will vest under the same conditions as the RSUs: the earlier of June 17, 2026, or the next annual meeting, subject to continued service.
• The reported transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following these transactions, Mr. Johnson directly beneficially owns 179,167 shares of Common Stock and 17,000 stock options.
• He also indirectly beneficially owns 75,000 shares through the NEJ09 IRREVOCABLE TRUST, 75,000 shares through the NEJ12 IRREVOCABLE TRUST, and 139,672 shares through Velocity Capital Management LLC.

Sentiment

Score: 7

Explanation: The acquisition of additional equity by a director, particularly through RSU and stock option awards, generally signals confidence in the company's future performance and aligns management's interests with shareholders. The transaction being under a 10b5-1 plan also adds a layer of transparency.

Positives

• Director David Michael Johnson's acquisition of 13,000 Restricted Stock Units (RSUs) and 17,000 stock options indicates continued confidence in Aura Biosciences' future prospects and aligns his interests with long-term shareholder value.
• The acquisition of RSUs at a $0 price and stock options at an exercise price of $6.18 provides a direct financial incentive for the director to contribute to the company's growth and stock performance.
• The transaction being made pursuant to a Rule 10b5-1 plan suggests a pre-planned, systematic approach to insider equity compensation, which is generally viewed positively as it reduces concerns about opportunistic trading.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports an increase in beneficial ownership by a director through equity compensation.

Risks

• NA

Future Outlook

The acquired Restricted Stock Units and Stock Options are subject to vesting upon the earlier of June 17, 2026, or the next annual meeting of the Issuer's stockholders, contingent on the Reporting Person's continued service.

Industry Context

This Form 4 filing reflects a routine insider transaction, common across publicly traded companies, where directors and executives receive equity compensation as part of their remuneration package. Such awards align management's interests with those of shareholders by tying compensation to the company's stock performance, a standard practice in the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• The equity compensation structure, involving Restricted Stock Units (RSUs) and stock options, is a standard practice in the biotechnology and pharmaceutical industries, similar to compensation models seen at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which often use equity awards to attract and retain top talent and align executive incentives with long-term shareholder value.

Related Party Transactions

• Indirect beneficial ownership of 75,000 Common Stock shares through the NEJ09 IRREVOCABLE TRUST, of which the Reporting Person is a trustee.
• Indirect beneficial ownership of 75,000 Common Stock shares through the NEJ12 IRREVOCABLE TRUST, of which the Reporting Person is a trustee.
• Indirect beneficial ownership of 139,672 Common Stock shares through Velocity Capital Management LLC, an entity of which the Reporting Person is the sole member.

Stakeholder Impact

• Shareholders: The increase in director ownership through equity awards can be viewed positively, as it aligns the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions.
• Employees: While not directly impacting all employees, the equity compensation structure for directors sets a precedent for how key personnel are incentivized, which can influence overall compensation philosophy.

Next Steps

• The acquired Restricted Stock Units and stock options are scheduled to vest upon the earlier of June 17, 2026, or the next annual meeting of Aura Biosciences' stockholders, subject to the director's continued service.

Key Dates

Keywords

Aura Biosciences, AURA, SEC Form 4, insider trading, beneficial ownership, stock options, restricted stock units, director, equity compensation, Rule 10b5-1